Literature DB >> 23720975

Tacrolimus in steroid resistant and steroid dependent childhood nephrotic syndrome.

Suroj Supavekin1, Wantanee Surapaitoolkorn, Thitima Kurupong, Thanaporn Chaiyapak, Nuntawan Piyaphanee, Anirut Pattaragarn, Achra Sumboonnanonda.   

Abstract

OBJECTIVE: To evaluate the efficacy of tacrolimus (Tac) in steroid resistant and steroid dependent nephrotic syndrome (NS) in children. MATERIAL AND
METHOD: Retrospective chart reviews of 18 children from outpatient clinic at the Department of Pediatrics, Faculty of Medicine Siriraj Hospital were diagnosed with steroid resistant (SR) and steroid dependent (SD) NS during 2002-2008 were enrolled in the present study
RESULTS: The boy to girl ratio was 2:1. The mean age at diagnosis was 6.0 years (1-14.4 years). There were nine SR and nine SDNS. Nine patients had focal segmental glomerulosclerosis (FSGS), 4 IgMnephropathy and two had minimal change diseases (MCD). Three children did not receive renal biopsy. All patients received prednisolone at the start of Tac. The average time from the diagnosis to initiation of Tac was 3.5 years (0.2-14years). The mean duration of Tac treatment was 1.3 year (0.3-6.2 years). The average Tac trough blood level was 4.09 mcg/L (1.3-9.9 mcg/L). The average dosage of Tac was 0.09 mg/kg/day (0.03-0.2 mg/kg/day). Thirteen (72.2%) children achieved complete response (CR). Five (27.80%) children did not respond to Tac. Nine (69.2%) children could stop prednisolone whereas four (30.8%) could lower prednisolone doses. The mean time to achieve CR was 24.6 days (0.1-3 months). The mean follow up period was 3.1 years (0.2-6.4 years). There was no change in an estimation of glomerular filtration rate (eGFR). In SRNS, there were CR in four (44.4%) and five (55.6%) children that FSGS did not respond to Tac. In SDNS, all responded to Tac and four (44.4%) children relapsed while on Tac and had upper respiratory tract infection (URI).
CONCLUSION: Tac is well-tolerated and effective treatment for SR and SDNS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23720975

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  6 in total

1.  Efficacy and safety of tacrolimus and low-dose prednisone in Chinese children with steroid-resistant nephrotic syndrome.

Authors:  Hai-Xia Chen; Qia Cheng; Fang Li; Qing-Nan He; Yan Cao; Zhu-Wen Yi; Xiao-Chuan Wu
Journal:  World J Pediatr       Date:  2019-05-02       Impact factor: 2.764

2.  Clinical efficacy and pharmacokinetics of tacrolimus in children with steroid-resistant nephrotic syndrome.

Authors:  Afsana Jahan; Ratna Prabha; Swasti Chaturvedi; Binu Mathew; Denise Fleming; Indira Agarwal
Journal:  Pediatr Nephrol       Date:  2015-07-02       Impact factor: 3.714

Review 3.  Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics.

Authors:  Guo-Xiang Hao; Lin-Lin Song; Dong-Feng Zhang; Le-Qun Su; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Br J Clin Pharmacol       Date:  2020-01-14       Impact factor: 4.335

4.  Population pharmacokinetics of tacrolimus in children with nephrotic syndrome.

Authors:  Guo-Xiang Hao; Xin Huang; Dong-Feng Zhang; Yi Zheng; Hai-Yan Shi; Yan Li; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Br J Clin Pharmacol       Date:  2018-05-22       Impact factor: 4.335

5.  Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models.

Authors:  Xiujin Shen; Hong Jiang; Meike Ying; Zhoutao Xie; Xiayu Li; Haibing Wang; Jie Zhao; Chuan Lin; Yucheng Wang; Shi Feng; Jia Shen; Chunhua Weng; Weiqiang Lin; Huiping Wang; Qin Zhou; Yan Bi; Meng Li; Lingyan Wang; Tongyu Zhu; Xiaoru Huang; Hui-Yao Lan; Jing Zhou; Jianghua Chen
Journal:  Sci Rep       Date:  2016-09-01       Impact factor: 4.379

6.  Intravenous cyclophosphamide induces remission in children with difficult to treat steroid resistant nephrotic syndrome from minimal change disease.

Authors:  Maha Haddad; Arundhati Kale; Lavjay Butani
Journal:  BMC Nephrol       Date:  2021-11-29       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.